Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telmisartan/Amlodipine FDC in Hypertension
NCT00553267Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2007
- Primary completion
- Oct 2008
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial of telmisartan in hypertension (HTN) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Change From Baseline in Trough Seated Diastolic Blood Pressure at 8 weeks. Started Nov 2007; status: completed.
02
Drugs
telmisartan
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT00553267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00553267.